GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cuorips 4894.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

6,460

+6.78%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Cuorips

Its shares trade on Tokyo Stock Exchange under the ticker 4894.T. It has been listed since 27 June 2023. In the fiscal year to 31 March 2026, it reported revenue of ¥212.3m and a net loss of ¥1.02bn. At that date it held total assets of ¥5.12bn and shareholders' equity of ¥4.75bn.

Cuorips Inc is a Japan-based company mainly engaged in the development and commercialization of regenerative medical products and contract development and manufacturing organization (CDMO) business. The company is headquartered in Chuo-Ku, Tokyo-To. The company went IPO on 2023-06-27. The main product of the Company is human iPS cell-derived cardiomyocyte sheets. The firm provides regenerative medical products for the heart and other areas through in-house research, joint research with universities and other research institutions and major pharmaceutical companies. The firm operates CDMO business using CLiC-1, a commercial cell culture and processing facility with an integrated laboratory based on the Company's original design concept.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
27 Jun 2023
Employees
46

Leadership

Pay as last reported

  • Mr. Takayuki KusanagiPresident, Chief Executive Officer, Representative Director, since 2020
  • Mr. Yoshiki SawaChief Technology Officer, Director
  • Mr. Manabu InoueVice President, Director, since 2020
  • Mr. Tadayuki TanimuraExecutive Officer
  • Mr. Tetsuya OhiraIndependent Director
  • Mr. Tadashi SamejimaIndependent Director
  • Mr. Ryohei ShimazakiIndependent Director
  • Mr. Kenichiro YoshidaIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Cuorips Inc's human iPS cell-derived cardiomyocyte sheets are a key product in regenerative medicine.
  • The company's CLiC-1 facility supports CDMO business with integrated laboratory capabilities.
  • Cuorips Inc's focus on heart regenerative products aligns with growing healthcare needs.

Weaknesses

  • Cuorips Inc has only 46 employees, which may limit scalability.
  • The company's IPO on 27 June 2023 indicates recent market entry.
  • Limited product range beyond heart regenerative medical products.

Opportunities

  • Expanding regenerative medical products for other body areas beyond the heart.
  • Collaborating with major pharmaceutical companies for joint research initiatives.
  • Growing demand for iPS cell-based therapies in the Japanese healthcare sector.

Threats

  • Competition from established biotechnology firms in Japan.
  • Regulatory challenges in the Japanese healthcare market.
  • Dependence on a single product line for revenue generation.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.